Certuity’s BioCryst Pharmaceuticals BCRX Stock Holding History

Certuity’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,000	Closed	-$30K	–	186
2020 Q1	$30K	Hold	15,000	–	–	0.02%	170
2019 Q4	$52K	Buy	+15,000	New	+$37.7K	0.02%	187

Other funds holding BCRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Certuity's BCRX Position: Q2 2020 in Review

Certuity sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2020, closing a stake of 15,000 shares — an estimated $30K sold.

Certuity first reported a position in BCRX in Q4 2019 and held it in 2 quarters. The position peaked at $52K in Q4 2019. 165 funds tracked by Wall St. Rank hold BCRX as of Q2 2020.

Certuity reported no remaining BioCryst Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Certuity sold 15,000 BioCryst Pharmaceuticals shares in Q2 2020, an estimated $30K.
Certuity first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 2 quarters.
Certuity's BioCryst Pharmaceuticals position peaked at $52K in Q4 2019.
165 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2020.

Based on Certuity's 13F filing for Q2 2020, filed 11 Aug 2020.